News Sentiment

MREO sentiment intelligence

Mereo BioPharma Group PLC ADR news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 48 Balanced news tone 50 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 0.34 Week of 10 Jul 2026
Weighted tone 48/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

74/100 classification confidence.

Company focus 41

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

+0.1% over one week, +9.8% over four weeks, trend inactive, and below fair value.

Latest direct headline Positive

Mereo BioPharma (MREO) Stock Edges Higher as Biotech Names Find Mixed Footing - Bear Pennant

Market Reaction

Balanced read

48/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 74/100 classification
One-week reaction 0.1% Price digesting
Trend fit Trend inactive 9.8% over four weeks
Fair value -85.6% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 6
Neutral 37
Negative 7

Relevance

Why the article matched

Direct first
Direct company coverage 41
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Market source 10
TradingKey 6
TradingView 6
Stock Titan 6
simplywall.st 5
The National Law Review 2
www.marketscreener.com 2
Investing.com 2

Event Lens

What the news is about

Classified themes
Earnings 19
Market update 19
Regulatory and legal 6
Balance sheet 3
Deals and strategy 2
Analyst action 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 50
TradingKey Direct company coverage

Mereo BioPharma Group PLC (MREO) Institutional Confidence

The article discusses the institutional confidence score for Mereo BioPharma Group PLC (MREO), which is currently 3.00, ranking 192 out of 386 in its industry. The institutional shareholding proportion has decreased by 38.82% quarter-over-quarter, with James Simons being the larg

Tone
Neutral 50/100
Event
Market update
Published
10 Jul 2026 19:39
Source
TradingKey
The National Law Review Direct company coverage

MREO Stockholders Have Opportunity to Lead Mereo BioPharma Group

A class action lawsuit has been filed against Mereo BioPharma Group plc (NASDAQ:MREO) and some of its officers by Bronstein, Gewirtz & Grossman, LLC. The lawsuit alleges that Mereo BioPharma made false and misleading statements about its Phase 3 ORBIT and COSMIC programs, which d

Tone
Negative 9/100
Event
Regulatory and legal
Published
30 Jun 2026 17:10
Source
The National Law Review
The National Law Review Direct company coverage

Bronstein, Gewirtz & Grossman, LLC Encourages Mereo BioPharma Group plc (MREO) Investors to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of Mereo BioPharma Group plc (NASDAQ:MREO) investors following a significant stock price drop. This drop occurred after Mereo announced that two Phase 3 studies for its treatment, setrusumab, failed to

Tone
Negative 30/100
Event
Regulatory and legal
Published
27 Jun 2026 15:11
Source
The National Law Review
TradingView Direct company coverage

Enterprise value to EBIT forward of Mereo BioPharma Group plc – NASDAQ:MREO

This article provides financial data for Mereo BioPharma Group plc (NASDAQ: MREO), specifically focusing on its enterprise value to EBIT forward. The content is presented within the context of TradingView's platform, offering an overview of the company's financial metrics. Howeve

Tone
Neutral 50/100
Event
Market update
Published
27 Jun 2026 03:38
Source
TradingView
TradingView Direct company coverage

Price to book forward of Mereo BioPharma Group plc – NASDAQ:MREO

This article focuses on the "Price to book forward" metric for Mereo BioPharma Group plc, traded under the ticker NASDAQ:MREO. It appears to be a stub or a section of a larger financial data presentation from TradingView, indicating specific financial metrics for the company. The

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 07:40
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of Mereo BioPharma Group plc – NASDAQ:MREO

The article focuses on the "Price to earnings forward" metric for Mereo BioPharma Group plc (NASDAQ: MREO). It notes that the market is currently closed with no trades, and the content primarily comprises extraneous website navigation and copyright information for TradingView and

Tone
Neutral 50/100
Event
Earnings
Published
25 Jun 2026 06:11
Source
TradingView
TradingKey Direct company coverage

Mereo BioPharma Group PLC (MREO) Financial Health: Profitability & Balance Sheet Analysis

This article analyzes the financial health of Mereo BioPharma Group PLC (MREO), assessing its profitability and balance sheet. The company has a robust financial status with a score of 7.61, ranking 100 out of 389 in its industry, although its operating efficiency is noted as low

Tone
Neutral 50/100
Event
Market update
Published
22 Jun 2026 12:10
Source
TradingKey
TradingKey Direct company coverage

Mereo BioPharma Group PLC (MREO) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Mereo BioPharma Group PLC (MREO), indicating its current valuation score is 7.17 within the Biotechnology & Medical Research industry. It details the company's valuation metrics, including a P/E ratio of -1.39, while noting that relev

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 10:39
Source
TradingKey
TradingKey Direct company coverage

Mereo BioPharma Group PLC (MREO) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Mereo BioPharma Group PLC (MREO), detailing its current price momentum score, support and resistance levels, and indicator readings. It includes signals from various technical indicators like MACD, RSI, and moving averages, suggesting

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 10:39
Source
TradingKey
TradingKey Direct company coverage

Mereo BioPharma Group PLC (MREO) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Mereo BioPharma Group PLC (MREO), indicating a strong earnings forecast score and a positive analyst rating. It details the average price target, expected revenue for the next quarter, and historical EPS performance. The report highl

Tone
Neutral 50/100
Event
Earnings
Published
18 Jun 2026 10:39
Source
TradingKey
TradingKey Direct company coverage

Mereo BioPharma Group PLC (MREO) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides historical data on dividends and stock splits for Mereo BioPharma Group PLC (MREO). It indicates that Mereo BioPharma has not distributed any dividends over the past five years and has no recorded stock split history. The page also presents current stock pri

Tone
Neutral 50/100
Event
Market update
Published
17 Jun 2026 22:11
Source
TradingKey
www.marketscreener.com Direct company coverage

Mereo BioPharma : to Participate in Fireside Chat at the Jefferies Global Healthcare Conference 2026

Mereo BioPharma Group plc will participate in a fireside chat at the Jefferies Global Healthcare Conference 2026 on June 4, 2026, featuring CEO Dr. Denise Scots-Knight. The clinical-stage biopharmaceutical company focuses on rare diseases and has product candidates for osteogenes

Tone
Positive 60/100
Event
Market update
Published
03 Jun 2026 14:47
Source
www.marketscreener.com
Finviz Direct company coverage

MREO - Mereo Biopharma Group Plc ADR Stock Price and Quote

This article provides comprehensive financial data and news for Mereo Biopharma Group Plc ADR (MREO), including its latest stock performance, key financial metrics, analyst ratings, and a chronological list of corporate news and press releases. The company is actively developing

Tone
Negative 32/100
Event
Analyst action
Published
30 May 2026 02:39
Source
Finviz
www.marketscreener.com Direct company coverage

Mereo Biopharma Group plc Announces Termination of Dr Annalisa Jenkins from Director, Effective May 14, 2026

Mereo Biopharma Group plc has announced that Dr. Annalisa Jenkins's appointment as a director was terminated, effective May 14, 2026. This information was reported by S&P Capital IQ. The company's stock, MREO, saw a minor dip of 0.29% on the day of the announcement, though it had

Tone
Neutral 50/100
Event
Market update
Published
26 May 2026 01:09
Source
www.marketscreener.com
openPR.com Direct company coverage

Mereo BioPharma Group plc (NASDAQ: MREO) Long Term Investor Alert: Investigation of potential Wrongdoing

A law firm has announced an investigation into potential breaches of fiduciary duties by directors and officers of Mereo BioPharma Group plc (NASDAQ: MREO) on behalf of current long-term investors. This follows a lawsuit alleging securities law violations related to overselling t

Tone
Negative 15/100
Event
Regulatory and legal
Published
20 May 2026 20:09
Source
openPR.com
Stock Titan Direct company coverage

EcoR1, Oleg Nodelman report 8.4% stake in Mereo (MREO)

EcoR1 Capital, LLC and Oleg Nodelman have jointly reported an 8.4% beneficial ownership stake in Mereo BioPharma Group plc (MREO) through an amended Schedule 13G/A filing. This includes shared voting and dispositive power over 66,844,275 Ordinary Shares, which are held via Americ

Tone
Neutral 50/100
Event
Deals and strategy
Published
15 May 2026 18:26
Source
Stock Titan
Stock Titan Direct company coverage

Bank of America reports 5.1% stake in Mereo BioPharma | MREO SEC Filing - Form SCHEDULE 13G

Bank of America Corporation has reported a 5.1% beneficial ownership stake in Mereo BioPharma Group plc (MREO), amounting to 40,976,460 ordinary shares. This disclosure was made via a SCHEDULE 13G SEC filing, indicating shared voting and dispositive power across Bank of America a

Tone
Neutral 50/100
Event
Deals and strategy
Published
14 May 2026 18:40
Source
Stock Titan
TipRanks Direct company coverage

Mereo BioPharma Shareholders Approve All AGM Resolutions

Mereo BioPharma Group plc shareholders approved all proposed resolutions at their Annual General Meeting on May 14, 2026. Key approvals included the 2025 annual report, auditor reappointment, executive pay, director reappointments, and the extension of share issuance authorities

Tone
Neutral 50/100
Event
Market update
Published
14 May 2026 15:39
Source
TipRanks
Investing.com Direct company coverage

Mereo BioPharma shareholders approve all resolutions at annual meeting

Mereo BioPharma Group plc announced that all resolutions were approved at its 2026 Annual General Meeting of Shareholders. This included the adoption of the annual report, re-appointment of PwC as auditors, approval of directors' remuneration and policy, and the re-appointment of

Tone
Positive 67/100
Event
Regulatory and legal
Published
14 May 2026 14:40
Source
Investing.com
Stock Titan Direct company coverage

Mereo BioPharma (NASDAQ: MREO) gains investor approval for pay and share issuance powers

Mereo BioPharma Group plc shareholders approved all resolutions at their 2026 Annual General Meeting, including the 2025 accounts, re-appointment of auditors PwC, director remuneration reports and policies, and the re-election of three directors. Investors also authorized the dir

Tone
Neutral 50/100
Event
Regulatory and legal
Published
14 May 2026 14:39
Source
Stock Titan
Stock Titan Direct company coverage

Mereo Biopharma (MREO) Stock News & Updates

This page provides news and updates for Mereo Biopharma (MREO), focusing on its rare-disease biopharmaceutical pipeline. Recent reports highlight financial results, clinical trial progress for setrusumab, alvelestat, and vantictumab, including successes in bone mineral density an

Tone
Negative 40/100
Event
Earnings
Published
14 May 2026 09:10
Source
Stock Titan
Eastern Progress Direct company coverage

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Mereo BioPharma Group plc of Class Action Lawsuit and Upcoming Deadlines - MREO

Pomerantz LLP has filed a class action lawsuit against Mereo BioPharma Group plc (MREO) on behalf of investors who suffered losses. The lawsuit alleges securities fraud following significant drops in Mereo's ADR price after clinical trial results for UX143 (setrusumab) failed to

Tone
Negative 16/100
Event
Regulatory and legal
Published
14 May 2026 02:10
Source
Eastern Progress
Market source Direct company coverage

Mereo BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate Updates

Mereo BioPharma reported its first quarter 2026 financial results, highlighting ongoing efforts to advance its rare disease pipeline. The company is engaging with regulatory agencies regarding setrusumab for pediatric osteogenesis imperfecta and seeking partners for alvelestat's

Tone
Positive 60/100
Event
Earnings
Published
13 May 2026 06:40
Source
Market source
AlphaStreet Direct company coverage

Mereo BioPharma Group Releases Q1 2026 Financial Results

Mereo BioPharma Group plc reported a narrower net loss for Q1 2026, posting -$0.01 diluted loss per share and a net loss of $6.7M. This improvement reflects the company's efforts to control expenses while advancing its therapeutic pipeline for rare diseases. Wall Street analysts

Tone
Neutral 50/100
Event
Earnings
Published
12 May 2026 13:40
Source
AlphaStreet